Early Phase 1Not yet recruitingPriority 4 · Lower priorityNCT05728879
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Plain-language summary
This trial is testing APR-TD011 (RLF-TD011) for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is an early Phase 1 trial, which means this is among the first tests of the treatment in patients, focusing on safety and dose. This trial is available at 1 location in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT): APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
APR-TD011 (RLF-TD011)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details